[1] |
Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must [J]. Autoimmun Rev, 2014, 13(7): 723-729.
|
[2] |
Czarnewski P, Das S, Parigi SM, et al. Retinoic acid and its role in modulating intestinal innate immunity [J]. Nutrients, 2017, 9(1): 68.
|
[3] |
Rhinn M, Dolle P. Retinoic acid signalling during development [J]. Development, 2012, 139(5): 843-858.
|
[4] |
Kurts C, Panzer U, Anders HJ, et al. The immune system and kidney disease: basic concepts and clinical implications [J]. Nat Rev Immunol, 2013, 13(10): 738-753.
|
[5] |
Dai Y, Chen A, Liu R, et al. Retinoic acid improves nephrotoxic serum-induced glomerulonephritis through activation of podocyte retinoic acid receptor alpha [J]. Kidney Int, 2017, 92(6): 1444-1457.
|
[6] |
Chen A, Lee K, D′Agati VD, et al. Bowman′s capsule provides a protective niche for podocytes from cytotoxic CD8+ T cells [J]. J Clin Invest, 2018, 128(8): 3413-3424.
|
[7] |
Kim CH. Control of innate and adaptive lymphocytes by the RAR-retinoic acid axis [J]. Immune Netw, 2018, 18(1): e1.
|
[8] |
Mallipattu SK, He JC. The beneficial role of retinoids in glomerular disease [J]. Front Med (Lausanne), 2015, 2(16): 1-5.
|
[9] |
Lehrke I, Schaier M, Schade K, et al. Retinoid receptor-specific agonists alleviate experimental glomerulonephritis [J]. Am J Physiol Renal Physiol, 2002, 282(4): F741-F751.
|
[10] |
Suzuki A, Ito T, Imai E, et al. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats [J]. J Am Soc Nephrol, 2003, 14(4): 981-991.
|
[11] |
Han SY, So GA, Jee YH, et al. Effect of retinoic acid in experimental diabetic nephropathy [J]. Immunol Cell Biol, 2004, 82(6): 568-576.
|
[12] |
Perez de Lema G, Lucio-Cazana FJ, Molina A, et al. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease [J]. Kidney Int, 2004, 66(3): 1018-1028.
|
[13] |
Natori Y, Ou ZL, Yamamoto-Shuda Y, et al. Expression of lymphotactin mRNA in experimental crescentic glomerulonephritis [J]. Clin Exp Immunol, 1998, 113(2): 265-268.
|
[14] |
Hill PA, Lan HY, Nikolic-Paterson DJ, et al. The ICAM-1/LFA-1 interaction in glomerular leukocytic accumulation in anti-GBM glomerulonephritis [J]. Kidney Int, 1994, 45(3): 700-708.
|
[15] |
Janssen U, Ostendorf T, Gaertner S, et al. Improved survival and amelioration of nephrotoxic nephritis in intercellular adhesion molecule-1 knockout mice [J]. J Am Soc Nephrol, 1998, 9(10): 1805-1814.
|
[16] |
Oseto S, Moriyama T, Kawada N, et al. Therapeutic effect of all-trans retinoic acid on rats with anti-GBM antibody glomerulonephritis [J]. Kidney Int, 2003, 64(4): 1241-1252.
|
[17] |
Rao J, Qian X, Wang P, et al. All-trans retinoic acid preconditioning protects against liver ischemia/reperfusion injury by inhibiting the nuclear factor kappa B signaling pathway [J]. J Surg Res, 2013, 180(2): e99-e106.
|
[18] |
Nozaki Y, Yamagata T, Sugiyama M, et al. Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis [J]. Clin Immunol, 2006, 119(3): 272-279.
|
[19] |
Na SY, Kang BY, Chung SW, et al. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB [J]. J Biol Chem, 1999, 274(12): 7674-7680.
|